Advertisement

Predictive Models in Tumor Immunology

  • Pier-Luigi Lollini
  • Arianna Palladini
  • Francesco Pappalardo
  • Santo Motta
Chapter
Part of the Modeling and Simulation in Science, Engineering and Technology book series (MSSET)

Keywords

Tumor Antigen Optimal Schedule Mammary Carcinoma Tumor Associate Antigen Vaccination Schedule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ada, G.L.: The immunological principles of vaccination. Lancet,335:8688, 523–526 (1990).CrossRefGoogle Scholar
  2. 2.
    Arlotti, L., Bellomo, N., De Angelis, E.: Generalized kinetic (Boltzmann) models: mathematical structures and applications. Mathematical Models and Methods in Applied Science,12:4, 567–591 (2002).MATHCrossRefGoogle Scholar
  3. 3.
    Bellomo, N., Preziosi, L.: Modelling and mathematical problems related to tumor evolution and its interaction with the immune system. Math. Comp. Model.,32, 413–452 (2000).MATHCrossRefMathSciNetGoogle Scholar
  4. 4.
    Chang, M.H., Shau, W.Y., Chen, C.J., Wu, T.C., Kong, M.S., Liang, D.C., Hsu, H.M., Chen, H.L., Hsu, H.Y., Chen, D.S.: Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA,284:23, 3040–3042 (2000).CrossRefGoogle Scholar
  5. 5.
    Croci, S., Nicoletti, G., Landuzzi, L., De Giovanni, C., Astolfi, A., Marini, C., Di Carlo, E., Musiani, P., Forni, G., Nanni, P., Lollini, P.-L.: Immunological prevention of a multigene cancer syndrome. Cancer Research,64, 8428–8434 (2004).CrossRefGoogle Scholar
  6. 6.
    De Angelis, E., Jabin, P.-E.: Mathematical models of therapeutical actions related to tumour and immune system competition. Math. Meth. Appl. Sci.,28:17, 2061–2083 (2005).MATHCrossRefGoogle Scholar
  7. 7.
    De Giovanni, C., Croci, S., Nicoletti, G., Landuzzi, L., Palladini, A., Pannellini, T., Borgia, L., Iezzi, M., Di Carlo, E., Orengo, A.M., Kennedy, R.C., Lollini, P.-L., Nanni, P., Musiani, P.: Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. Int. J. Cancer,121:88, (2007).Google Scholar
  8. 8.
    De Giovanni, C., Nicoletti, G., Landuzzi, L., Astolfi, A., Croci, S., Comes, A., Ferrini, S., Meazza, R., Iezzi, M., Di Carlo, E., Musiani, P., Cavallo, F., Nanni, P., Lollini, P.-L.: Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Research,64:11, 4001–4009 (2004).CrossRefGoogle Scholar
  9. 9.
    Dorne, C., Dorigo, M., Glover, F.: New ideas in optimization. Advanced Topics in Computer Science, McGraw-Hill, New York (1999).Google Scholar
  10. 10.
    Lollini, P.-L., Cavallo, F., Nanni, P., Forni, G.: Vaccines for tumour prevention. Nat. Rev. Cancer,6:3, 204–216 (2006).CrossRefGoogle Scholar
  11. 11.
    Lollini, P.-L., De Giovanni, C., Pannellini, T., Cavallo, F., Forni, G., Nanni, P.: Cancer immunoprevention. Future Oncol.,1:1, 57–66 (2005).CrossRefGoogle Scholar
  12. 12.
    Lollini, P.-L., Forni, G.: Cancer immunoprevention: tracking down persistent tumor antigens. Trends Immunol.,24:2, 62–66 (2003).CrossRefGoogle Scholar
  13. 13.
    Lollini, P.-L., Motta, S., Pappalardo, F.: Discovery of cancer vaccination protocols with a genetic algorithm driving an agent based simulator. BMC Bioinformatics,7:352, doi:10.1186/1471-2105-7-352 (2006).CrossRefGoogle Scholar
  14. 14.
    Lollini, P.-L., Nicoletti, G., Landuzzi, L., De Giovanni, C., Rossi, I., Di Carlo, E., Musiani, P., Muller, W.J., Nanni, P.: Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. Int. J. Cancer,77:6, 937–941 (1998).CrossRefGoogle Scholar
  15. 15.
    Motta, S., Lollini, P.-L., Castiglione, F., Pappalardo, F.: Modelling vaccination schedules for a cancer immunoprevention vaccine. Immunome Research,1:5, doi:10.1186/1745-7580-1-5 (2005).CrossRefGoogle Scholar
  16. 16.
    Nanni, P., Landuzzi, L., Nicoletti, G., De Giovanni, C., Rossi, I., Croci, S., Astolfi, A., Iezzi, M., Di Carlo, E., Musiani, P., Forni, G., Lollini, P.-L.: Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J. Immunol.,173:4, 2288–2296 (2004).Google Scholar
  17. 17.
    Nanni, P., Nicoletti, G., De Giovanni, C., Landuzzi, L., Di Carlo, E., Cavallo, F., Pupa, S.M., Rossi, I., Colombo, M.P., Ricci, C., Astolfi, A., Musiani, P., Forni, G., Lollini, P.-L.: Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med.,194:9, 1195–1205 (2001).CrossRefGoogle Scholar
  18. 18.
    Nanni, P., Pupa, S.M., Nicoletti, G., De Giovanni, C., Landuzzi, L., Rossi, I., Astolfi, A., Ricci, C., De Vecchi, R., Invernizzi, A.M., Di Carlo, E., Musiani, P., Forni, G., Menard, S., Lollini, P.-L.: p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int. J. Cancer,87:2, 186–194 (2000).CrossRefGoogle Scholar
  19. 19.
    Nemhauser, G.L., Wolsey, L.A.: Integer and combinatorial optimization. Wiley, New York (1988).MATHGoogle Scholar
  20. 20.
    Novellino, L., Castelli, C., Parmiani, G.: A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother., (2004).Google Scholar
  21. 21.
    Pappalardo, F., Lollini, P.-L., Castiglione, F., Motta, S.: Modelling and simulation of cancer immunoprevention vaccine. Bioinformatics,21:12, 2891–2897 (2005).CrossRefGoogle Scholar
  22. 22.
    Pappalardo, F., Mastriani, E., Lollini, P.-L., Motta, S.: Genetic algorithm against cancer. Lecture Notes in Computer Science,3849, 223–228 (2006).CrossRefGoogle Scholar
  23. 23.
    Quaglino, E., Iezzi, M., Mastini, C., Amici, A., Pericle, F., Di Carlo, E., Pupa, S.M., De Giovanni, C., Spadaro, M., Curcio, C., Lollini, P.-L., Musiani, P., Forni, G., Cavallo, F.: Electroporated DNA vaccine clears away multifocal mammary carcinomas in Her-2/neu transgenic mice. Cancer Res.,64:8, 2858–2864 (2004).CrossRefGoogle Scholar
  24. 24.
    Rosenberg, S.A., Yang, J.C., Restifo, N.P.: Cancer immunotherapy: moving beyond current vaccines. Nat. Med.,10:9, 909–915 (2004).CrossRefGoogle Scholar
  25. 25.
    Ross, J.S., Gray, K., Gray, G.S., Worland, P.J., Rolfe, M.: Anticancer antibodies. Am. J. Clin. Pathol.,119:4, 472–485 (2003).CrossRefGoogle Scholar
  26. 26.
    Sawaya, G.F., Smith-McCune, K.: HPV vaccination–more answers, more questions. N. Engl. J. Med.,356:19, 1991–1993 (2007).CrossRefGoogle Scholar
  27. 27.
    Smyth, M.J., Dunn, G.P., Schreiber, R.D.: Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol.,90, 1–50 (2006).CrossRefGoogle Scholar
  28. 28.
    Waldmann, T.A., Morris, J.C.: Development of antibodies and chimeric molecules for cancer immunotherapy. Adv. Immunol.,90, 83–131 (2006).CrossRefGoogle Scholar

Copyright information

© Birkhäuser Boston 2008

Authors and Affiliations

  • Pier-Luigi Lollini
    • 1
  • Arianna Palladini
    • 1
  • Francesco Pappalardo
    • 2
  • Santo Motta
    • 2
  1. 1.Sezione di Cancerologia Dipartimento di Patologia SperimentaleUniversit‘a di BolognaItaly
  2. 2.Dipartimento di Matematica e InformaticaUniversit‘a di CataniaItaly

Personalised recommendations